Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Synaptogenix, Inc. (TAOX : NSDQ)

• Company Description    Synaptogenix Inc. is an emerging biopharmaceutical company. It focused on developing therapies for neurodegenerative diseases. The company's lead therapeutic candidate consist Bryostatin-1. Synaptogenix Inc. is based in NEW YORK. Number of Employees: 4

• Price / Volume Information    Yesterday's Closing Price: $7.98 Daily Weekly Monthly 20 Day Moving Average: 345,056 shares Shares Outstanding: 1.39 (millions) Market Capitalization: $11.09 (millions) Beta: 1.90 52 Week High: $9.00 52 Week Low: $1.88 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 64.20% 58.05% 12 Week 277.30% 217.36% Year To Date 129.97% 115.37%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 1185 Avenue of the Americas 3rd Floor - New York,NY 10036 USA ph: 973-242-0005 fax: - ir@synaptogen.com http://www.synaptogen.com

• General Corporate Information    Officers Alan J. Tuchman - Chief Executive Officer Joshua N. Silverman - Chairman William S. Singer - Vice-Chairman Robert Weinstein - Chief Financial Officer Bruce T. Bernstein - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 87167T300 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/25 Next Expected EPS Date: 08/13/25 Share - Related Items Shares Outstanding: 1.39 Most Recent Split Date: 4.00 (0.04:1) Beta: 1.90 Market Capitalization: $11.09 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $ Payout Ratio: Number of Estimates in the Fiscal Year Consensus: Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/13/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 2.15 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: 109.76% vs. Previous Quarter: 100.92% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 06/30/25 - - 03/31/25 - -115.28 12/31/24 - -86.55 ROA 06/30/25 - - 03/31/25 - -58.31 12/31/24 - -52.38 Current Ratio 06/30/25 - - 03/31/25 - 72.59 12/31/24 - 17.48 Quick Ratio 06/30/25 - - 03/31/25 - 72.59 12/31/24 - 17.48 Operating Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Net Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Pre-Tax Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Book Value 06/30/25 - - 03/31/25 - 3.72 12/31/24 - 4.33 Inventory Turnover 06/30/25 - - 03/31/25 - - 12/31/24 - - Debt-to-Equity 06/30/25 - - 03/31/25 - 0.00 12/31/24 - 0.00 Debt-to-Capital 06/30/25 - - 03/31/25 - 0.00 12/31/24 - 0.00

Powered by Zacks Investment Research ©